Brief: Compugen Announces First Patient Dosed In Com902 Phase 1 Trial For Patients With Advanced Malignancies
06/04/2020 13:52
April 6 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES FIRST PATIENT DOSED IN COM902 PHASE 1
TRIAL
FOR PATIENTS WITH ADVANCED MALIGNANCIES
Source text for Eikon: ID:nPn5jqZbwa
Further company coverage: CGEN.TA
(Reuters.Briefs@thomsonreuters.com)
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025